Xeris Biopharma Holdings Inc. (XERS)

Business: Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies for patient populations in endocrinology, neurology, and gastroenterology.

IPO Date: 21-Jun-2018

Chairman & CEO: Mr. Paul R. Edick

Pres & COO: Mr. John P. Shannon

Listing: NASDAQ: XERS

Country: United States

Headquarters: Chicago, IL

Website: https://www.xerispharma.com

Market cap: $220.92 Mln

Revenue (TTM): $63.68 Mln

Earnings (TTM): $-138.03 Mln

Cash: $132.15 Mln

Total Debt: $137.98 Mln

Insider's Holding: 2.64%

Liquidity: Low

52 Week range: $1.25 - 4.79

Shares outstanding: 135,531,008

6 Years Aggregate:

• CFO: $-377.47 Mln
• EBITDA: $-407.29 Mln
• Net Profit: $-439.29 Mln